Showing results (181-190 of 224) with videos related to

Sort By:
Pageof 23
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 3, 2021
Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase III trial in patients with gastroesophageal adenocarcinomaK Shitara, M Özgüroğlu, Y-J Bang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 28, 2022
Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142T André, S Lonardi, K Y M Wong, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 23, 2014
Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II studyE Van Cutsem, C Boni, J Tabernero, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 1, 2026
A randomised study of encorafenib, cetuximab, and FOLFIRI versus FOLFIRI with or without bevacizumab in BRAF V600E-mutant colorectal cancer: BREAKWATER Cohort 3S Kopetz, J Tabernero, S Lonardi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 9, 2014
Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial datasetH Blons, J F Emile, K Le Malicot, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 2, 2001
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III studyE Van Cutsem, C Twelves, J Cassidy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 23, 2017
A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trialM H Kulke, P Ruszniewski, E Van Cutsem, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 4, 2021
Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE studyM Tempero, D-Y Oh, J Tabernero, et al.
Pageof 23